Articles tagged with Erythropoiesis
A multinational study found that erythropoietin treatment does not prevent death or disability in newborns with critically low levels of oxygen or blood supply to the brain. The research compared outcomes between babies treated with controlled cooling and those receiving both erythropoietin and cooling, but showed no benefit from the a...
A study by Kumamoto University researchers reveals that ApoE plays a crucial role in promoting hematopoietic stem cells to produce more red blood cells in response to acute anemia. This mechanism differs from the previously known pathway and may pave the way for new treatments for patients with severe anemia.
β-Thalassemia patients experience iron overload due to increased intestinal absorption and transfusions, leading to oxidative stress and tissue damage. Chelation therapy is the cornerstone of treatment, but novel therapeutic strategies are needed to optimize patient outcomes.
Researchers used NIRS to track oxygenated hemoglobin levels in infant brains responding to gentle touch. They found similar response times across age groups, but varying signal amplitudes that may be linked to changes in blood flow and erythropoietin production.
Scientists have identified Norn cells as the primary source of erythropoietin (Epo) in humans, a crucial hormone for red blood cell production. This breakthrough could lead to the development of new treatments for anemia and other conditions related to impaired Epo production.
Researchers at Kyoto University discovered METTL16's role in DNA repair and erythropoiesis, a process generating 200 billion new red blood cells daily. Tiny methyl groups on specific mRNAs play a pivotal role in this process, involving mechanisms mediated by RNA-binding proteins.
Two new studies found that dialysis facilities owned by nephrologists may provide better care, with patients receiving home dialysis more often. Additionally, a shorter interval between dialysis and surgery was associated with improved post-surgery survival rates.
Researchers at Brigham and Women's Hospital identified a new genetic cause of erythropoietic protoporphyria (EPP), a photosensitive blood disorder. A dominant mutation in the CLPX gene was found to lead to excess porphyrin production, contributing to EPP.
Research at Cold Spring Harbor Laboratory investigated how transcriptional activity is connected to a cell's nucleus location. The study reveals that changes in the nucleus' position can significantly impact gene expression and cell behavior.
In the Phase 2 study, Aranesp demonstrated a significant erythroid response and improvements in hemoglobin levels and fatigue among low-risk MDS patients. The study found that 70% of patients with no prior erythropoietic agent use achieved an erythroid response and 67% reached target hemoglobin levels.
A Brg1 mutation in mice reveals the importance of SWI/SNF complexes in beta-globin regulation and erythropoiesis. This study may provide insight into common ailments such as beta thalassemia and anemia. The findings highlight the significance of chromatin-remodeling complexes in development and physiology.
A Phase 2 study of Aranesp(R) demonstrates a 77% overall response rate in low-risk MDS patients with anemia. Patients who had never received erythropoietic therapy responded well to Aranesp, while those with prior treatment showed continued efficacy.
Researchers have developed a gene therapy technique that can produce and secrete proteins into the bloodstream indefinitely, without the need for viral delivery systems. This could drastically decrease the cost of treatments for certain types of anemia, which affect over 140,000 people in the US annually.